FDA-approved medicines exist for specific indications

HCG

Labeled fertility glycoprotein (urinary hCG / choriogonadotropin alfa) — ASIH papers are misuse context, not PE.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock — labeled fertility / reproductive-medicine object. Human chorionic gonadotropin (hCG) is a placental glycoprotein hormone (common α-subunit + hCG β-subunit; UniProt α-chain P01215). Pharmaceutical objects include urinary-derived hCG and recombinant choriogonadotropin alfa (Ovidrel-class) used as ovulation trigger and in selected male hypogonadotropic hypogonadism / infertility pathways. PubChem “chorionic gonadotropin” small-molecule hits are identity traps — do not badge a steroid-ring CID. hCG is not a research “peptide stack” ingredient in evidence grading. Marked separately: literature on anabolic-steroid-induced hypogonadism (ASIH) discussing hCG appears as misuse / recovery-context clinical commentary — not as performance-enhancement endorsement. This drawer marks papers. It is not use advice.

Bottom line

Approved reproductive-medicine uses (ovulation triggering; selected male HH/infertility regimens) have substantial clinical literature. Hyperglycosylated hCG is a related biochemical species in pregnancy biology. ASIH / post-AAS recovery papers describe clinical problems and endocrine management debates — they must not be read as a green light for physique-enhancing hCG use. Refuse performance-enhancement glow.

Papers

Hormone biology / labeled reproductive framing

PMID 28505106 — Theofanakis 2017

Tested: review of human chorionic gonadotropin as the pregnancy hormone and broader biology.

Does not show: a sports or physique indication.

PMID 17346790 — Cole 2007

Tested: review of hyperglycosylated hCG as a distinct glycoform in pregnancy biology.

Does not show: that hyperglycosylated hCG is the pharmaceutical trigger product identity.

PMID 30674181 — Dosouto 2019

Tested: review of advances in ovulation-trigger strategies (includes hCG and dual-trigger contexts in IVF).

Does not show: non-fertility uses.

PMID 24842671 — Griffin 2014

Tested: dual trigger with GnRH agonist plus standard-dose hCG to improve oocyte maturity rates (IVF clinical report).

Does not show: male physique applications.

PMID 16949587 — Kenigsberg 2006

Tested: IVF stimulation using low-dose recombinant choriogonadotropin alfa as LH-activity source (pharmaceutical recombinant object).

Does not show: urinary hCG interchangeability without product framing, or non-ART use.

Male hypogonadism / infertility — labeled reproductive medicine

PMID 30159241 — Lee 2018

Tested: review of indications for hCG in management of infertility in hypogonadal men (andrology/reproductive framing).

Does not show: endorsement of AAS-cycle adjunct use.

PMID 39901824 — Esteves 2026

Tested: review of hCG-based clinical treatments for infertile men with non-obstructive azoospermia.

Does not show: performance-enhancement efficacy.

PMID 38128110 — Alexander 2024

Tested: systematic review/meta-analysis of gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism.

Does not show: adult bodybuilding protocols.

PMID 26488941 — La Vignera 2016

Tested: clinical commentary comparing hCG vs testosterone approaches in late-onset hypogonadism framing.

Does not show: a universal preference or sports license; reproductive/endocrine clinic context only.

Misuse / ASIH context (not PE endorsement)

PMID 24636400 — Rahnema 2014

Tested: review of anabolic steroid-induced hypogonadism — diagnosis and treatment (includes hCG among discussed endocrine tools).

Does not show: that ASIH management literature validates physique-enhancing hCG use; marks a clinical complication pathway.

PMID 30929329 — Tatem 2020

Tested: review of managing anabolic steroid-induced infertility and related strategies.

Does not show: performance-enhancement advice; fertility-preservation/recovery medicine context.

What is not established

Any performance-enhancement or “PCT peptide” grade for hCG. That urinary hCG, recombinant choriogonadotropin alfa, and pregnancy glycoforms are interchangeable without product identity. That ASIH commentary papers are efficacy endorsements. Product identity for unregulated hCG preparations. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

28505106 17346790 30674181 24842671 16949587 30159241 39901824 38128110 26488941 24636400 30929329

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.